gtan

You are here

Bio

Gene Tan is an assistant professor at the J. Craig Venter Institute working in the Infectious Disease group. The focus of his research is on virus-host interactions by defining the immunological, molecular and genetic determinants that govern immunity and disease. The aim is to better understand how viruses manipulate the host machinery to replicate and in turn elucidate the mechanisms by which the host counteracts the pathogen. Analyses of virus-host interaction can then facilitate the development of better diagnostic tools, novel therapeutics and vaccines.

Prior to his appointment at JCVI, Dr. Tan was a post-doctoral fellow at the Icahn School of Medicine at Mount Sinai working on characterizing the immunological and structural determinants of protection against influenza virus and Zika virus. He received his doctorate from Thomas Jefferson University and his undergraduate degree from the Philadelphia College of Pharmacy and Science.

Research Priorities

Characterization of the structural and immunological determinants of protection against viral pathogens:

  • Elucidate the mechanisms by which antibodies neutralize virus and protect in vivo.
  • Emphasis on developing novel methods in isolating monoclonal antibodies from human peripheral blood mononuclear cell (PBMC) compartment.

Characterization of virus-host interaction by defining the molecular and transcriptional response

  • Emphasis on respiratory and neurotropic pathogens.

Patents

Vaccines for use in the prophylaxis and treatment of influenza virus disease (Pat. No. US20170114103)

Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.
Nature communications. 2017-10-10; 8.1: 846.
PMID: 29018261
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-18; 113.42: 11931-11936.
PMID: 27698132
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-04; 113.40: E5944-E5951.
PMID: 27647907
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.
Cell host & microbe. 2016-06-08; 19.6: 800-13.
PMID: 27281570
Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
PLoS pathogens. 2016-04-01; 12.4: e1005578.
PMID: 27081859
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.
Journal of virology. 2016-01-13; 90.7: 3789-93.
PMID: 26764009
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
Antimicrobial agents and chemotherapy. 2015-07-01; 59.7: 4162-72.
PMID: 25941218
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
The Journal of clinical investigation. 2015-03-02; 125.3: 1255-68.
PMID: 25689254
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Journal of virology. 2014-12-01; 88.23: 13580-92.
PMID: 25210195
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.
Nature medicine. 2014-02-01; 20.2: 143-51.
PMID: 24412922
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.
Journal of virology. 2012-06-01; 86.11: 6179-88.
PMID: 22491456
The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription.
Proceedings of the National Academy of Sciences of the United States of America. 2007-04-24; 104.17: 7229-34.
PMID: 17438267